S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Major Financial Crisis Could Hit America (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Major Financial Crisis Could Hit America (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Major Financial Crisis Could Hit America (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Major Financial Crisis Could Hit America (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Major Financial Crisis Could Hit America (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Major Financial Crisis Could Hit America (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Major Financial Crisis Could Hit America (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Major Financial Crisis Could Hit America (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus

Coronavirus Therapeutics Stocks List

Compare coronavirus therapeutics stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$221.88
+1.7%
$235.87
$211.71
$296.67
$118.56 B0.642.40 million shs2.50 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$77.72
-0.2%
$80.77
$57.17
$89.74
$96.94 B0.395.83 million shs5.74 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$750.27
+1.4%
$780.93
$538.01
$837.55
$82.03 B0.23597,858 shs541,082 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.30
-5.4%
$0.31
$0.16
$3.09
$139.25 M1.9552.69 million shs949,399 shs
AbbVie Inc. stock logo
ABBV
AbbVie
$136.86
0.0%
$151.48
$131.10
$168.11
$241.46 B0.586.00 million shs4.21 million shs
GSK plc stock logo
GSK
GSK
$34.28
+0.5%
$36.11
$28.47
$44.75
$70.19 B0.673.32 million shs1.65 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and
$444.26
+0.4%
$400.21
$283.11
$454.95
$421.72 B0.363.18 million shs2.08 million shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+1.75%+2.28%-6.19%-2.99%-10.69%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-0.22%+0.82%-2.55%-3.19%+22.49%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+1.39%+3.48%-1.55%-3.05%+19.02%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%+2.47%+19.18%-15.20%-82.74%
AbbVie Inc. stock logo
ABBV
AbbVie
-0.01%-0.51%-7.55%-10.51%-7.01%
GSK plc stock logo
GSK
GSK
+0.50%+0.12%-7.30%+0.73%-19.76%
Eli Lilly and Company stock logo
LLY
Eli Lilly and
+0.44%+4.34%+3.85%+43.02%+47.28%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
2.6812 of 5 stars
2.14.05.03.92.21.71.9
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
3.2031 of 5 stars
2.35.04.24.11.92.53.8
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.4865 of 5 stars
3.43.00.03.71.82.51.9
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.0206 of 5 stars
3.50.00.04.42.00.00.6
AbbVie Inc. stock logo
ABBV
AbbVie
2.7176 of 5 stars
2.25.04.23.91.22.51.9
GSK plc stock logo
GSK
GSK
2.4518 of 5 stars
0.05.03.30.02.60.01.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and
2.8489 of 5 stars
2.44.03.34.01.32.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.15
Hold$250.9413.10% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.53
Moderate Buy$91.0017.09% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.74
Moderate Buy$854.1313.84% Upside
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.50
Moderate Buy$9.002,949.81% Upside
AbbVie Inc. stock logo
ABBV
AbbVie
2.43
Hold$163.4019.39% Upside
GSK plc stock logo
GSK
GSK
2.09
Hold$1,576.884,499.99% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and
2.73
Moderate Buy$425.05-4.32% Downside

Current Analyst Ratings

Latest Coronavirus Therapeutics Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$440.00 ➝ $500.00
5/24/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$447.00 ➝ $498.00
5/24/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$450.00 ➝ $500.00
5/16/2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$90.00 ➝ $100.00
5/15/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$478.00 ➝ $507.00
5/8/2023
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$960.00 ➝ $935.00
5/5/2023
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMaintains
5/5/2023
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$880.00 ➝ $927.00
5/5/2023
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$976.00 ➝ $895.00
5/4/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$430.00 ➝ $505.00
5/4/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$430.00 ➝ $475.00
(Data available from 6/6/2020 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$26.32B4.50$24.76 per share8.96$6.86 per share32.34
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.28B3.55$8.95 per share8.68$16.91 per share4.60
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$12.17B6.74$45.14 per share16.62$207.31 per share3.62
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M2.31N/AN/A$0.26 per share1.14
AbbVie Inc. stock logo
ABBV
AbbVie
$58.05B4.16$18.70 per share7.32$9.78 per share13.99
GSK plc stock logo
GSK
GSK
$36.28B1.93$4.48 per share7.65$5.79 per share5.92
Eli Lilly and Company stock logo
LLY
Eli Lilly and
$28.54B14.78$9.21 per share48.26$11.34 per share39.18

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$6.55B$14.7115.0811.521.7230.23%248.47%13.54%8/3/2023 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$4.59B$4.4317.5410.710.9020.65%39.35%13.11%8/1/2023 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.34B$36.8020.3920.582.3733.81%20.41%15.79%8/2/2023 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$428.33MN/A0.00N/AN/A-818.22%-282.82%-57.64%N/A
AbbVie Inc. stock logo
ABBV
AbbVie
$11.84B$4.2332.3512.402.4913.37%153.92%16.91%8/4/2023 (Estimated)
GSK plc stock logo
GSK
GSK
$18.50B$8.284.148.811.7047.85%43.27%8.55%7/26/2023 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and
$6.24B$6.2970.6336.812.2020.54%61.42%12.74%8/3/2023 (Estimated)

Latest Coronavirus Therapeutics Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/26/2023N/A
GSK plc stock logo
GSK
GSK
$0.84N/A-$0.84N/AN/AN/A
4/27/2023Q1 2023
Amgen Inc. stock logo
AMGN
Amgen
$3.84$3.98+$0.14$2.68$6.18 billion$6.11 billion    
4/27/2023Q1 2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.63$1.37-$0.26$1.94$6.33 billion$6.35 billion    
4/27/2023Q1 2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.44$2.46+$0.02$4.79$12.23 billion$12.23 billion    
4/27/2023Q1 23
Eli Lilly and Company stock logo
LLY
Eli Lilly and
$1.73$1.62-$0.11$1.75$6.87 billion$6.96 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$8.523.84%+10.14%57.92%11 Years
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.003.86%+5.03%67.72%8 Years
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
AbbVie Inc. stock logo
ABBV
AbbVie
$5.924.33%+9.16%139.95%51 Years
GSK plc stock logo
GSK
GSK
$1.363.97%N/A16.43%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and
$4.521.02%+15.02%71.86%9 Years

Latest Coronavirus Therapeutics Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/26/2023
GSK plc stock logo
GSK
GSK
quarterly$0.34755.6%5/18/20235/19/20237/13/2023
4/25/2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Quarterly$0.753.65%6/14/20236/15/20236/29/2023
5/1/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and
quarterly$1.131.11%5/12/20235/15/20236/9/2023
3/7/2023
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.133.73%5/17/20235/18/20236/8/2023
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
11.36
3.14
2.79
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.10
1.28
1.13
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.11
5.45
4.67
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.14
0.88
0.79
AbbVie Inc. stock logo
ABBV
AbbVie
4.46
0.96
0.82
GSK plc stock logo
GSK
GSK
1.47
0.95
0.69
Eli Lilly and Company stock logo
LLY
Eli Lilly and
1.67
1.30
1.02

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
75.53%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
78.72%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
84.25%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
34.48%
AbbVie Inc. stock logo
ABBV
AbbVie
67.71%
GSK plc stock logo
GSK
GSK
13.15%
Eli Lilly and Company stock logo
LLY
Eli Lilly and
82.13%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.57%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.21%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
8.83%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
AbbVie Inc. stock logo
ABBV
AbbVie
0.26%
GSK plc stock logo
GSK
GSK
10.00%
Eli Lilly and Company stock logo
LLY
Eli Lilly and
0.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
25,200534.33 million531.28 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.25 billion1.24 billionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
11,851109.33 million99.67 millionOptionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
799471.88 million459.61 millionOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.76 billion1.76 billionOptionable
GSK plc stock logo
GSK
GSK
69,4002.05 billion1.84 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and
39,000949.27 million948.04 millionOptionable

Coronavirus Therapeutics Stocks Headlines

SourceHeadline
ASCO 2023: Novartis and Lilly make progress in early breast cancer treatmentsASCO 2023: Novartis and Lilly make progress in early breast cancer treatments
bioworld.com - June 5 at 7:44 PM
The Department of Health – Abu Dhabi and Eli Lilly Suisse S.A sign Declaration of CollaborationThe Department of Health – Abu Dhabi and Eli Lilly Suisse S.A sign Declaration of Collaboration
zawya.com - June 5 at 9:43 AM
Eli Lilly and (NYSE:LLY) Upgraded by StockNews.com to "Strong-Buy"Eli Lilly and (NYSE:LLY) Upgraded by StockNews.com to "Strong-Buy"
americanbankingnews.com - June 5 at 3:26 AM
Eli Lilly (NYSE:LLY) jumps 3.9% this week, though earnings growth is still tracking behind five-year shareholder returnsEli Lilly (NYSE:LLY) jumps 3.9% this week, though earnings growth is still tracking behind five-year shareholder returns
finance.yahoo.com - June 4 at 2:42 PM
Insider Selling: Eli Lilly and Company (NYSE:LLY) EVP Sells 6,000 Shares of StockInsider Selling: Eli Lilly and Company (NYSE:LLY) EVP Sells 6,000 Shares of Stock
americanbankingnews.com - June 3 at 8:02 AM
Patrik Jonsson Sells 6,000 Shares of Eli Lilly and Company (NYSE:LLY) StockPatrik Jonsson Sells 6,000 Shares of Eli Lilly and Company (NYSE:LLY) Stock
marketbeat.com - June 2 at 5:15 PM
Aldebaran Capital LLC Makes New $2.88 Million Investment in Eli Lilly and Company (NYSE:LLY)Aldebaran Capital LLC Makes New $2.88 Million Investment in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - June 2 at 2:54 PM
UPDATE 1-Novartis drug cuts recurrence risk by 25% in early-stage breast cancerUPDATE 1-Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
finance.yahoo.com - June 2 at 1:15 PM
China’s XtalPi to Gain USD250 Million by Teaming With Eli Lilly on Small DrugsChina’s XtalPi to Gain USD250 Million by Teaming With Eli Lilly on Small Drugs
yicaiglobal.com - June 2 at 8:14 AM
Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual MeetingLilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting
finance.yahoo.com - June 2 at 8:14 AM
Novartis drug cuts recurrence risk by 25% in early-stage breast cancerNovartis drug cuts recurrence risk by 25% in early-stage breast cancer
finance.yahoo.com - June 2 at 8:14 AM
3 BRILLIANT MINUTES: Treating Alzheimer’s with sound and light3 BRILLIANT MINUTES: Treating Alzheimer’s with sound and light
msn.com - June 2 at 3:14 AM
20 Best Healthcare Dividend Stocks to Invest in (LLY)20 Best Healthcare Dividend Stocks to Invest in (LLY)
marketbeat.com - June 1 at 11:56 AM
Obesity and Alzheimers news makes Eli Lilly world’s most valuable drugmakerObesity and Alzheimer's news makes Eli Lilly world’s most valuable drugmaker
japantimes.co.jp - June 1 at 8:35 AM
Eli Lilly settles class-action insulin lawsuit for $13.5MEli Lilly settles class-action insulin lawsuit for $13.5M
ibj.com - May 31 at 3:48 PM
Eltrekibart by Eli Lilly and Co for Hidradenitis Suppurativa: Likelihood of ApprovalEltrekibart by Eli Lilly and Co for Hidradenitis Suppurativa: Likelihood of Approval
pharmaceutical-technology.com - May 31 at 10:48 AM
XtalPi to collaborate with Eli Lilly on using AI and robotics in drug discoveryXtalPi to collaborate with Eli Lilly on using AI and robotics in drug discovery
technode.com - May 31 at 10:48 AM
XtalPi announces $250m AI drug discovery collaboration with Eli LillyXtalPi announces $250m AI drug discovery collaboration with Eli Lilly
pharmaceutical-technology.com - May 31 at 10:48 AM
Eli Lilly partners with XtalPi on AI drug discovery in up to $250M dealEli Lilly partners with XtalPi on AI drug discovery in up to $250M deal
seekingalpha.com - May 31 at 12:23 AM
Eli Lil­ly set­tles in­sulin pric­ing law­suit for $13.5M, month­ly out-of-pock­et com­mit­mentEli Lil­ly set­tles in­sulin pric­ing law­suit for $13.5M, month­ly out-of-pock­et com­mit­ment
endpts.com - May 30 at 7:22 PM
Eli Lilly And Company LtdEli Lilly And Company Ltd
reuters.com - May 30 at 7:22 PM
Eli Lilly Unusual Options Activity For May 30Eli Lilly Unusual Options Activity For May 30
msn.com - May 30 at 2:22 PM
Eli Lilly agrees to $500M settlement in insulin lawsuit, agrees to $35 price capEli Lilly agrees to $500M settlement in insulin lawsuit, agrees to $35 price cap
benefitspro.com - May 30 at 2:22 PM
XtalPi Announces Collaboration with Lilly, Using AI + Robotics to Uncover First-in-class TherapeuticsXtalPi Announces Collaboration with Lilly, Using AI + Robotics to Uncover First-in-class Therapeutics
technews.tmcnet.com - May 30 at 9:21 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Amgen logo

Amgen

NASDAQ:AMGN
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

NASDAQ:REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Sorrento Therapeutics logo

Sorrento Therapeutics

NASDAQ:SRNE
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.
AbbVie logo

AbbVie

NYSE:ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
GSK logo

GSK

NYSE:GSK
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Commercial Operations, Research and Development, and Consumer Healthcare. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Eli Lilly and logo

Eli Lilly and

NYSE:LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

My Account -